These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34509272)

  • 21. Changings and Challenges in Liver Transplantation for Nonalcoholic Fatty Liver Disease/Steatohepatitis.
    Shalaby S; Battistella S; Zanetto A; Bizzaro D; Germani G; Paolo Russo F; Burra P
    Clin Liver Dis; 2023 May; 27(2):225-237. PubMed ID: 37024204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease.
    Haflidadottir S; Jonasson JG; Norland H; Einarsdottir SO; Kleiner DE; Lund SH; Björnsson ES
    BMC Gastroenterol; 2014 Sep; 14():166. PubMed ID: 25260964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological features of fatty liver disease.
    Yeh MM; Brunt EM
    Gastroenterology; 2014 Oct; 147(4):754-64. PubMed ID: 25109884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histological Features of Cerebellar Neuropathology in Patients With Alcoholic and Nonalcoholic Steatohepatitis.
    Balzano T; Forteza J; Borreda I; Molina P; Giner J; Leone P; Urios A; Montoliu C; Felipo V
    J Neuropathol Exp Neurol; 2018 Sep; 77(9):837-845. PubMed ID: 30016459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alcoholic and Nonalcoholic Fatty Liver Disease and Incident Hospitalization for Liver and Cardiovascular Diseases.
    Chang Y; Cho J; Cho YK; Cho A; Hong YS; Zhao D; Ahn J; Sohn CI; Shin H; Guallar E; Ryu S
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):205-215.e7. PubMed ID: 31085337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China.
    Yang RX; Zou ZS; Zhong BH; Deng H; He FP; Shi JP; Zhao CY; Mi YQ; Zhou YJ; Di FS; Zheng RD; Du Q; Shang J; Popovic B; Chen J; Fan JG
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):426-432. PubMed ID: 34246549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights.
    Ikejima K; Kon K; Yamashina S
    Clin Mol Hepatol; 2020 Oct; 26(4):728-735. PubMed ID: 33053942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets.
    Eguchi A; Iwasa M; Nakagawa H
    Liver Int; 2023 Feb; 43(2):292-298. PubMed ID: 36462157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alcoholic and non-alcoholic steatohepatitis.
    Neuman MG; French SW; French BA; Seitz HK; Cohen LB; Mueller S; Osna NA; Kharbanda KK; Seth D; Bautista A; Thompson KJ; McKillop IH; Kirpich IA; McClain CJ; Bataller R; Nanau RM; Voiculescu M; Opris M; Shen H; Tillman B; Li J; Liu H; Thomes PG; Ganesan M; Malnick S
    Exp Mol Pathol; 2014 Dec; 97(3):492-510. PubMed ID: 25217800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science.
    Brar G; Tsukamoto H
    J Gastroenterol; 2019 Mar; 54(3):218-225. PubMed ID: 30643981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MAFLD vs NAFLD: Where are we?
    Mantovani A
    Dig Liver Dis; 2021 Oct; 53(10):1368-1372. PubMed ID: 34108096
    [No Abstract]   [Full Text] [Related]  

  • 32. Coffee Intake and Liver Steatosis: A Population Study in a Mediterranean Area.
    Veronese N; Notarnicola M; Cisternino AM; Reddavide R; Inguaggiato R; Guerra V; Rotolo O; Zinzi I; Leandro G; Correale M; Tutino V; Misciagna G; Osella AR; Bonfiglio C; Giannelli G; Caruso MG;
    Nutrients; 2018 Jan; 10(1):. PubMed ID: 29342916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical and biochemical characteristics in patients with histology compatible with steatothepatitis in National Hospital Arzobispo Loayza, Lima, Peru, from 2010 to 2012].
    Alegría Matos PH; Tafur Cabello KS; Lozano Miranda A; Loza Munarriz C; Lozano Miranda Z
    Rev Gastroenterol Peru; 2015; 35(3):236-42. PubMed ID: 26397280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease.
    Tannapfel A; Denk H; Dienes HP; Langner C; Schirmacher P; Trauner M; Flott-Rahmel B
    Virchows Arch; 2011 May; 458(5):511-23. PubMed ID: 21442288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Non-alcoholic steatohepatitis - from NAFLD to MAFLD].
    Balmer ML; Dufour JF
    Ther Umsch; 2011 Apr; 68(4):183-8. PubMed ID: 21452138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis.
    Henry ZH; Argo CK
    Gastroenterol Clin North Am; 2020 Mar; 49(1):45-62. PubMed ID: 32033764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease.
    Sookoian S; Pirola CJ
    PLoS One; 2013; 8(3):e58895. PubMed ID: 23516571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease? - A mechanistic hypothesis.
    de Medeiros IC; de Lima JG
    Med Hypotheses; 2015 Aug; 85(2):148-52. PubMed ID: 25956735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased Renal Expression of Complement Components in Patients With Liver Diseases: Nonalcoholic Steatohepatitis, Alcohol-Associated, Viral Hepatitis, and Alcohol-Viral Combination.
    Frost KL; Jilek JL; Thompson AD; Klein RR; Sinari S; Torabzedehkorasani E; Billheimer DD; Schnellmann RG; Cherrington NJ
    Toxicol Sci; 2022 Aug; 189(1):62-72. PubMed ID: 35789393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease.
    Tada T; Kumada T; Toyoda H; Saibara T; Ono M; Kage M
    Biomarkers; 2018; 23(4):328-334. PubMed ID: 29308929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.